sr141716 has been researched along with n-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (52.63) | 29.6817 |
| 2010's | 9 (47.37) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, Y; Fong, TM; Goulet, MT; Hagmann, WK; Jewell, JP; Kumar, S; Lanza, TJ; Lao, J; Lin, LS; Liu, P; Marsh, DJ; Qi, H; Rosko, K; Samuel, K; Shah, SK; Shearman, LP; Shen, CP; Strack, A; Stribling, DS; Tong, X; Van der Ploeg, LH; Wang, J; Xiao, JC; Xu, SS; Yin, W | 1 |
| Ball, RG; Castonguay, LA; Doss, GA; Fong, TM; Goulet, MT; Ha, S; Hagmann, WK; Lin, LS; Shen, CP; Tsou, NN; Xiao, JC | 1 |
| Alig, L; Alsenz, J; Andjelkovic, M; Bénardeau, A; Bendels, S; Bleicher, K; Bourson, A; David-Pierson, P; Guba, W; Hildbrand, S; Kube, D; Lübbers, T; Mayweg, AV; Narquizian, R; Neidhart, W; Nettekoven, M; Plancher, JM; Rocha, C; Rogers-Evans, M; Röver, S; Schneider, G; Taylor, S; Waldmeier, P | 1 |
| Chang, CH; Jung, ME; Kang, SY; Kim, J; Kim, MA; Lee, J; Lee, SH; Na, J; Park, HJ; Park, JH; Seo, HJ; Song, KS; Yoo, J; Yun, H | 1 |
| Benwell, K; Brooks, TD; Foloppe, N; Kennett, G; Knight, AR; Misra, A; Monck, NJ | 1 |
| Erdélyi, P; Fischer, J; Gyertyán, I; Hegyi, E; Kiss, B; Laszy, J; Páyer-Lengyel, D; Szabó, G; Szemzo, A; Szikra, J; Varga, B; Vastag, M; Vukics, K | 1 |
| Han, HK; Jung, ME; Kang, SY; Kim, J; Kim, MJ; Kim, MS; Lee, J; Lee, M; Lee, SH; Seo, HJ; Son, EJ; Song, KS | 1 |
| Balasubrahmanyam, D; Chaudhury, H; Jadhav, VP; Kannan, M; Khan, SK; Mohan, P; Nadipalli, P; Nanduri, S; Neelima Devi, B; Nyavanandi, VK; Rawoof, KA; Sasmal, PK; Sebastian, VJ; Shiva Kumar, K; Srinivas, P; Srinivasa Reddy, D; Swetha, J; Talwar, R; Venkatesham, B | 1 |
| Chorvat, RJ | 1 |
| Azzara, AV; Baska, RA; Behnia, K; Carlson, KE; Cullen, MJ; Devenny, JJ; Ellsworth, BA; Everlof, GG; Ewing, WR; Godonis, HE; Gu, Z; Gudmundsson, O; Harvey, SJ; Johnghar, S; Kang, L; Keim, WJ; Lee, N; Murphy, BJ; Murugesan, N; Pelleymounter, MA; Ranasinghe, A; Rohrbach, KW; Sher, PM; Sitkoff, DF; Stetsko, PI; Sulsky, RB; Thomas, MA; Wu, G; Wu, X; Yang, Y; Yu, G; Zhu, Y; Zuvich, E | 1 |
| Aronne, LJ; Davis, SN; Foster, GD; Pagotto, U | 1 |
| Fong, TM; Heymsfield, SB | 1 |
| Immenschuh, S | 1 |
| Berrendero, F; Burokas, A; Gispert, JD; Heyne, A; Kiesselbach, C; Maldonado, R; Martín, M; Martín-García, E; Millán, O; Rubí, B | 1 |
| Balendran, A; Cheng, L; Clapham, JC; Hjorth, S; Vauquelin, G; Wennerberg, M | 1 |
| Cervino, C; Pagotto, U; Pasquali, R; Vicennati, V | 1 |
| Cahill, K; Ussher, MH | 1 |
| Bedros, JR; Medvegy, M; Pados, G; Simonyi, G | 1 |
| Fabisiak, A; Fabisiak, N; Fichna, J; Storr, M; Włodarczyk, M | 1 |
5 review(s) available for sr141716 and n-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide
| Article | Year |
|---|---|
Peripherally restricted CB1 receptor blockers.
Topics: Animals; Brain; Cocaine; Drug Discovery; Humans; Liver Diseases; Metabolic Diseases; Morpholines; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Sulfonamides | 2013 |
Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions.
Topics: Aged; Amides; Anti-Obesity Agents; Dose-Response Relationship, Drug; Eating; Energy Metabolism; Female; Humans; Male; Obesity; Piperidines; Pyrazoles; Pyridines; Receptor, Cannabinoid, CB1; Rimonabant | 2009 |
Cannabinoid type 1 receptor antagonists for smoking cessation.
Topics: Amides; Body Weight; Humans; Piperidines; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Secondary Prevention; Smoking; Smoking Cessation; Smoking Prevention | 2011 |
[The pharmacological treatment of obesity: past, present and future].
Topics: Amides; Anti-Obesity Agents; Anticonvulsants; Antidepressive Agents; Basal Metabolism; Benzazepines; Benzoxazines; Body Mass Index; Bridged Bicyclo Compounds, Heterocyclic; Ciliary Neurotrophic Factor; Clinical Trials as Topic; Combined Modality Therapy; Cyclobutanes; Dexfenfluramine; Fatty Acids; Female; Fenfluramine; Glucagon-Like Peptide 1; Human Growth Hormone; Humans; Intestinal Absorption; Lactones; Leptin; Life Style; Liraglutide; Male; Norepinephrine; Obesity; Obesity, Morbid; Orlistat; Piperidines; Pyrazoles; Pyridines; Receptor, Melanocortin, Type 4; Rimonabant; Satiation; Serotonin; Sodium-Glucose Transport Proteins; Sucrose; Thyroid Hormones | 2012 |
Gastrointestinal Adverse Events of Cannabinoid 1 Receptor Inverse Agonists suggest their Potential Use in Irritable Bowel Syndrome with Constipation: A Systematic Review and Meta-Analysis.
Topics: Amides; Cannabinoid Receptor Antagonists; Constipation; Gastrointestinal Agents; Gastrointestinal Diseases; Humans; Irritable Bowel Syndrome; Mental Disorders; Pyridines; Rimonabant | 2019 |
14 other study(ies) available for sr141716 and n-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide
| Article | Year |
|---|---|
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
Topics: Animals; Anti-Obesity Agents; Body Weight; Cannabinoids; Cyclic AMP; Eating; Humans; Liver; Microsomes; Obesity; Rats; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2 | 2006 |
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
Topics: Amides; Amino Acid Sequence; Animals; Binding Sites; Cells, Cultured; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Crystallography, X-Ray; Humans; Hydrogen Bonding; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Molecular Sequence Data; Molecular Structure; Mutagenesis, Site-Directed; Pyridines; Receptor, Cannabinoid, CB1; Reference Standards; Sequence Alignment; Structure-Activity Relationship | 2008 |
Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity.
Topics: Animals; Anti-Obesity Agents; Benzodioxoles; Body Weight; Crystallography, X-Ray; Cyclohexanols; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Humans; Hypothermia; Ligands; Male; Mice; Microsomes; Models, Molecular; Molecular Structure; Obesity; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Structure-Activity Relationship | 2008 |
Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
Topics: Administration, Oral; Animals; Biological Availability; Computer Simulation; Crystallography, X-Ray; Dose-Response Relationship, Drug; Humans; Male; Mice; Mice, Inbred C57BL; Models, Chemical; Models, Molecular; Molecular Structure; Obesity; Oxadiazoles; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Stereoisomerism; Structure-Activity Relationship | 2008 |
Discovery and functional evaluation of diverse novel human CB(1) receptor ligands.
Topics: Animals; Cannabinoids; Cannabis; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Humans; Ligands; Mice; Models, Chemical; Molecular Structure; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant | 2009 |
Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists.
Topics: Animals; Anti-Obesity Agents; Body Weight; Cattle; Drug Design; Eating; Humans; Lipids; Pyrazoles; Rats; Receptor, Cannabinoid, CB1; Structure-Activity Relationship | 2009 |
Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.
Topics: Animals; CHO Cells; Cricetinae; Cricetulus; Humans; Male; Mice; Mice, Inbred C57BL; Obesity; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Structure-Activity Relationship; Thiadiazoles | 2010 |
Structure-activity relationship studies of novel pyrazole and imidazole carboxamides as cannabinoid-1 (CB1) antagonists.
Topics: Aminoimidazole Carboxamide; Animals; Body Weight; Dose-Response Relationship, Drug; Humans; Mice; Mice, Inbred C57BL; Molecular Structure; Pyrazoles; Receptor, Cannabinoid, CB1; Stereoisomerism; Structure-Activity Relationship | 2011 |
Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.
Topics: Animals; Cytochrome P-450 Enzyme System; Drug Discovery; Half-Life; Protein Binding; Pyridazines; Rats; Receptor, Cannabinoid, CB1; Structure-Activity Relationship; Triazoles | 2013 |
The endocannabinoid system as a target for obesity treatment.
Topics: Amides; Anti-Obesity Agents; Cannabinoid Receptor Modulators; Cyclobutanes; Depression; Endocannabinoids; Humans; Lactones; Life Style; Metabolic Syndrome; Obesity; Orlistat; Piperidines; Pyrazoles; Pyridines; Rimonabant; Risk | 2008 |
Endocannabinoid signalling as an anti-inflammatory therapeutic target in atherosclerosis: does it work?
Topics: Amides; Animals; Atherosclerosis; Cannabinoid Receptor Modulators; Disease Models, Animal; Endocannabinoids; Humans; Macrophages; Mice; Piperidines; Pyrazoles; Pyridines; Reactive Oxygen Species; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Signal Transduction | 2009 |
Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant.
Topics: Amides; Analysis of Variance; Animals; Autoradiography; Benzoxazines; Body Weight; Brain; Cyclohexanols; Diet Fads; Disease Models, Animal; Eating; Female; Guanosine 5'-O-(3-Thiotriphosphate); International Cooperation; Morpholines; Naphthalenes; Obesity; Piperidines; Protein Binding; Pyrazoles; Pyridines; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Sulfur Isotopes; Time Factors; Tomography Scanners, X-Ray Computed; Tritium; Whole Body Imaging | 2010 |
Binding properties of antagonists to cannabinoid receptors in intact cells.
Topics: Amides; HEK293 Cells; Humans; Ligands; Piperidines; Protein Binding; Pyrazoles; Pyridines; Receptor, Cannabinoid, CB1; Rimonabant; Serum Albumin, Bovine; Sulfones; Time Factors | 2011 |
Feeding disorders and obesity.
Topics: Amides; Animals; Cannabinoid Receptor Modulators; Clinical Trials as Topic; Eating; Energy Metabolism; Feeding and Eating Disorders; Humans; Islets of Langerhans; Liver; Muscle, Skeletal; Obesity; Piperidines; Pyrazoles; Pyridines; Receptor, Cannabinoid, CB1; Rimonabant | 2009 |